ARKG or IHI or XBI

Key Takeaways

• ARK Genomic Revolution ETF (ARKG) is an actively managed thematic fund focused on genomics innovation with a higher expense ratio of 0.75% and concentrated holdings in smaller-cap companies.
• iShares U.S. Medical Devices ETF (IHI) offers passive exposure to the medical devices sector through a rules-based index with a moderate expense ratio of 0.38% and approximately 50 holdings.
• SPDR S&P Biotech ETF (XBI) provides equal-weighted passive exposure to the biotechnology industry with the lowest expense ratio of 0.35% and broader diversification across more than 150 holdings.
• Structural differences include active management in ARKG versus passive indexing in IHI and XBI, leading to varying levels of concentration risk and rebalancing frequency.
• Expense efficiency favors XBI and IHI over ARKG, while thematic tilt and volatility profiles differ based on sub-sector focus within healthcare.
• Relative positioning in recent market cycles highlights XBI's equal-weight methodology as a potential mitigator of single-stock concentration compared to the other two funds.

Introduction

ARK Genomic Revolution ETF (ARKG), iShares U.S. Medical Devices ETF (IHI), and SPDR S&P Biotech ETF (XBI) represent distinct approaches to healthcare innovation within the biotechnology and medical technology space. ARKG pursues an active, thematic strategy centered on genomics advancements, while IHI tracks a passive index of U.S. medical device companies and XBI follows an equal-weighted biotechnology index. These ETFs compete in overlapping yet differentiated segments of the healthcare sector, offering investors tiered exposures ranging from concentrated innovation bets to broader sector diversification. The comparison highlights variations in management style, cost structure, and risk profiles relevant for portfolio allocation decisions in the current environment.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014 that seeks long-term capital growth by investing at least 80% of assets in domestic and foreign equity securities tied to the genomics revolution theme. The fund typically holds 40 to 60 positions, with top holdings including companies such as 10x Genomics Inc (TXG), Twist Bioscience Corp (TWST), Tempus AI Inc (TEM), CRISPR Therapeutics AG (CRSP), and Personalis Inc (PSNL). Sector allocation centers heavily on healthcare, particularly health technology, with additional exposure to information technology and related areas. Its expense ratio stands at 0.75%, reflecting active management costs. Distinguishing features include discretionary stock selection by ARK Investment Management and a focus on multi-cap growth companies advancing gene editing, molecular diagnostics, and bio-informatics.

iShares U.S. Medical Devices ETF (IHI) Overview

iShares U.S. Medical Devices ETF (IHI) is a passively managed fund launched in 2006 that seeks to track the performance of the Dow Jones U.S. Select Medical Equipment Index. The index measures the medical equipment sector of the U.S. equity market, encompassing manufacturers and distributors of devices such as imaging scanners, prosthetics, and pacemakers. The ETF holds approximately 50 securities, providing targeted exposure to the medical devices sub-sector. Its expense ratio is 0.38%. Key structural characteristics include physical replication of the index, quarterly rebalancing aligned with index methodology, and a focus on established U.S. companies within healthcare equipment. The fund maintains a non-diversified structure but offers liquid access to this specialized industry segment.

SPDR S&P Biotech ETF (XBI) Overview

SPDR S&P Biotech ETF (XBI) is a passively managed exchange-traded fund launched in 2006 that seeks to track the S&P Biotechnology Select Industry Index, representing the biotechnology segment of the S&P Total Market Index. The index employs a modified equal-weighted methodology across more than 150 holdings, reducing concentration risk relative to market-cap weighted peers. Top positions typically include a broad array of biotechnology firms with weights around 1-2% each. Its expense ratio is 0.35%, among the lowest in the category. Distinguishing features encompass quarterly index rebalancing, equal-weight construction that favors smaller and mid-cap biotech names, and comprehensive coverage of the biotechnology sub-industry within healthcare.

Industry and Thematic Landscape

The healthcare innovation sector encompassing genomics, medical devices, and biotechnology continues to experience capital flows driven by advancements in precision medicine, regulatory approvals for novel therapies, and macroeconomic factors such as aging populations and healthcare spending trends. Earnings momentum among major holdings reflects ongoing research and development investments alongside clinical trial outcomes. Geopolitical influences and supply chain considerations affect device manufacturers, while broader sector risks include policy changes around drug pricing and reimbursement. These external dynamics influence all three ETFs through their shared healthcare exposure, though sub-sector tilts create differentiated sensitivities to innovation cycles and economic conditions.

Performance and Positioning Comparison

In recent market cycles, performance differences among ARK Genomic Revolution ETF (ARKG), iShares U.S. Medical Devices ETF (IHI), and SPDR S&P Biotech ETF (XBI) stem from their structural variances. ARKG's active, concentrated approach has shown higher volatility and greater sensitivity to individual company developments within genomics. IHI's passive medical devices focus has delivered more stable returns tied to established equipment providers, with moderate drawdowns during sector rotations. XBI's equal-weighted biotechnology exposure has demonstrated resilience through broader participation across holdings, potentially tempering the impact of any single stock's movement compared to more concentrated peers. Relative positioning reflects XBI's diversification benefits and lower costs supporting consistency, while ARKG's thematic tilt introduces elevated risk-adjusted volatility in innovation-driven environments.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Tickeron AI Verdict

Based on observable structural characteristics, SPDR S&P Biotech ETF (XBI) presents the strongest combination of cost efficiency at 0.35%, broad diversification through equal weighting across more than 150 holdings, and stable positioning within the biotechnology theme. This profile supports favorable risk-adjusted attributes relative to the active concentration in ARK Genomic Revolution ETF (ARKG) and the narrower medical devices focus in iShares U.S. Medical Devices ETF (IHI). Tickeron’s AI would currently favor XBI with high probability for investors seeking balanced healthcare exposure.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations